The big picture on nanomedicine: the state of investigational and approved nanomedicine products

doi:10.1016/j.nano.2012.05.013

Nanomedicine: Nanotechnology, Biology and Medicine

Volume 9, Issue 1, January 2013, Pages 1-14

https://doi.org/10.1016/j.nano.2012.05.013 Get rights and content

Abstract

Developments in nanomedicine are expected to provide solutions to many of modern medicine's unsolved problems, so it is no surprise that the literature contains many articles discussing the subject. However, existing reviews tend to focus on specific sectors of nanomedicine or to take a very forward-looking stance and fail to provide a complete perspective on the current landscape. This article provides a more comprehensive and contemporary inventory of nanomedicine products. A keyword search of literature, clinical trial registries, and the Web yielded 247 nanomedicine products that are approved or in various stages of clinical study. Specific information on each was gathered, so the overall field could be described based on various dimensions, including FDA classification, approval status, nanoscale size, treated condition, nanostructure, and others. In addition to documenting the many nanomedicine products already in use in humans, this study indentifies several interesting trends forecasting the future of nanomedicine.

From the Clinical Editor

In this one of a kind review, the state of nanomedicine commercialization is discussed, concentrating only on nanomedicine-based developments and products that are either in clinical trials or have already been approved for use.

Graphical Abstract

Section snippets

Scope of analysis

The definitions of “nanotechnology” and “nanomedicine” continue to be an area of controversy, with no universally accepted classification. Because an operational definition is required for the purposes of this study, nanomedicine is taken as the use of nanoscale or nanostructured materials in medicine, engineered to have unique medical effects based on their structures, including structures with at least one characteristic dimension up to 300 nm. Nanomedicine takes advantage of two general

Methods

We used a structured sequence of Internet searches to identify nanomedicine applications and products. Targeted searches on PubMed.gov, Google, and Google Scholar, and a number of clinical trial registries produced a range of resources, including journal articles, consumer websites, commercial websites, clinical trial summaries, manufacturer documents, conference proceedings, and patents. All of those were used to identify potential nanomedicine applications and products. Information was

Results

The targeted search of clinical trial registries yielded 1,265 potentially relevant clinical trial results. Duplicate results and trials involving clearly non-nano applications or products were eliminated, leaving 789 clinical trials with potential nanomedicine applications or products. The application/product name and company was identified for each of these trials, yielding a total of 141 unique applications and products (many were associated with multiple trials). Thirty-eight of these were

Discussion

This study identified a significant number of nanomedicine products approved for or nearing in-human use. It is difficult to extrapolate these numbers directly, because growth in medical industries is so heavily influenced by swings in the economy and regulatory processes. However, we observed some definite trends related to the future of nanomedicine. The most prominent theme throughout is the relative adolescence of the field. Although all the applications identified represent significant

Acknowledgments

The contents of this article are solely the responsibility of the authors and do not necessarily represent the views of NIH or NHGRI. Thanks to the “Nanodiagnostics and Nanotherapeutics: Building Research Ethics and Oversight” Working Group for valuable input on methodology and analysis.

References (123)

N. Sozer et al.
Nanotechnology and its applications in the food sector
Trends Biotechnol
(2009)
S.K. Sahoo et al.
Nanotech approaches to drug delivery and imaging
Drug Disc Today
(2003)
K.K. Jain
Nanotechnology in clinical laboratory diagnostics
Clin Chim Acta
(2005)
H. Liu et al.
Nanomedicine for implants: a review of studies and necessary experimental tools
Biomaterials
(2007)
E. Engel et al.
Nanotechnology in regenerative medicine: the materials side
Trends Biotechnol
(2008)
B. Van Eerdenbrugh et al.
Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products
Int J Pharma
(2008)
D.C. Litzinger et al.
Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta (BBA) -
Biomembranes
(1994)
D.P. O'Neal et al.
Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles
Cancer Lett
(2004)
M.J.D. Clift et al.
The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line
Toxicol Appl Pharmacol
(2008)
L.H. Lindner
Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: Active ingredient and mediator of drug release
J Control Release
(2008)

A.H. Faraji et al.

Nanoparticles in cellular drug delivery

Bioorg Med Chem

(2009)

X. Zhang et al.

Quantitative analysis of SPIO and USPIO uptake rate by macrophages: effects of particle size, concentration, and labeling time

Proc Intl Soc Mag Reson Med

(2001)

K.D. Jandt et al.

Future perspectives of resin-based dental materials

Dent Mater

(2009)

M.A. Rauschmann

Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections

Biomaterials

(2005)

M. Sato et al.

Increased osteoblast functions on undoped and yttrium-doped nanocrystalline hydroxyapatite coatings on titanium

Biomaterials

(2006)

M. Law et al.

Nanowire dye-sensitized solar cells

Nat Mater

(2005)

C.K. Chan et al.

High-performance lithium battery anodes using silicon nanowires

Nat Nano

(2008)

P. Vettiger et al.

The ‘millipede’ - nanotechnology entering data storage

IEEE Trans Nanotechnol

(2002)

S. De Franceschi et al.

Electronics and the single atom

Nature

(2002)

S.A. Wickline et al.

Nanotechnology for molecular imaging and targeted therapy

Circulation

(2003)

S. Nie et al.

Nanotechnology applications in cancer

Biomed Engin

(2007)

N. Nasongkla et al.

Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems

Nano Lett

(2006)

B. Sumer et al.

Theranostic nanomedicine for cancer

Nanomedicine

(2008)

V. Wagner et al.

The emerging nanomedicine landscape

Nature Biotechnol

(2006)

V. Wagner et al.

Nanomedicine: drivers for development and possible impacts

JRC-IPTS, Eur

(2006)

H. Jamil

Liposomes: the next generation

Mod Drug Discov

(2004)

D.D. Lasic et al.

Medical Applications of Liposomes

(1998)

W.C. Zamboni

Concept and clinical evaluation of carrier-mediated anticancer agents

Oncologist

(1998)

R. Bawa

Nanoparticle-based therapeutics in humans: a survey

NLB

(2008)

P. Shah et al.

Nanoemulsion: a pharmaceutical review

Syst Rev Pharm

(2010)

G.P. Krestin

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

Eur Radiol

(2001)

M.L. Hayman

The emerging product and patent landscape for nanosilver-containing medical devices

NLB

(2009)

Y.W.H. Wong et al.

Selected applications of nanotechnology in textiles

AUTEX Res J

(2009)

M.G. Dobson et al.

Emerging technologies for point-of-care genetic testing

Expert Rev Mol Diagn

(2007)

Nanomedicine - Global Strategic Business Report

Nanotechnology in Health Care to 2014 - Market Size, Market Share, Market Leaders, Demand Forecast, Sales, Company Profiles, Market Research, Industry Trends and Companies

NNI What is nanotechnology

A.M. Smith et al.

Semiconductor nanocrystals: structure, properties, and band gap engineering

Acc Chem Res

(2010)

M.-C. Daniel et al.

Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology

Chem Revs

(2004)

NCT00848042: Pilot study of Aurolaser™ therapy in refractory and/or recurrent tumors of the head and neck. Full text view

L.Y. Chou et al.

Strategies for the intracellular delivery of nanoparticles

Chem Soc Rev

(2010)

B.D. Chithrani et al.

Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells

Nano Lett

(2006)

P. Decuzzi et al.

Intravascular delivery of particulate systems: does geometry really matter?

Pharm Res

(2009)

A. Hauptman et al.

Envisioned developments in nanobiotechnology—Nano2Life expert survey report

(2005)

Nanotechnology and medicine / Nanotechnology medical applications. The Project on Emerging Nanotechnologies 2011

Elan Drug Technologies - NanoCrystal® Technology

FDA Basics

S.A. Shaffer et al.

In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

Cancer Chemother Pharmacol

(2006)

L.R. Morgan et al.

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

Cancer Chemother Pharmacol

(2006)

E. Kanaoka

A novel and simple type of liposome carrier for recombinant interleukin-2

J Pharm Pharmacol

(2001)

Cited by (832)

Placenta-anchored tadalafil liposomes rescues intrauterine growth restriction through continuous placental blood perfusion improvement
2024, Journal of Controlled Release
Physiological or pathological hypoperfusion of the placenta is one of the main causes of intrauterine growth restriction (IUGR) which poses a significant risk to the health of the fetus and newborn. Tadalafil, a 5-type phosphodiesterase inhibitor, has previously been found to improve the symptoms of IUGR in various clinical studies. Unfortunately, its clinical utility is hindered by its limited water solubility, rapid metabolism, and lack of specific distribution in target tissues rendering tadalafil unable to maintain long-term placental perfusion. In this study, iRGD-modified tadalafil-loaded liposomes (iRGD-lipo@Tad) featuring a size of approximately 480 nm were designed to rectify the shortcomings of tadalafil. The prepared iRGD-lipo@Tad exhibited superior stability, sustained drug release capacity, and low cytotoxicity. The fluorescence study, tissue slice study, and drug biodistribution study together demonstrated the placenta-anchored ability of iRGD-modified liposomes. This was achieved by a dual approach consisting of the iRGD-mediated placenta-targeting effect and special particle size-mediated placenta resident effect. The pharmacokinetic study revealed a significant improvement in the in vivo process of tadalafil encapsulated by the iRGD-modified liposomes. In comparison to the tadalafil solution, the peak plasma concentration of iRGD-lipo@Tad was significantly increased, and the area under the curve was increased by about 7.88 times. In the pharmacodynamic study, iRGD-lipo@Tad achieved a continuous and efficient improvement of placental blood perfusion. This was achieved by decreasing the ratio of plasma soluble fms-like tyrosine kinase to placental growth factor and increasing the levels of cyclic guanosine monophosphate and nitric oxide. Consequently, iRGD-lipo@Tad resulted in a significant increase in embryo weight and a reduction in the miscarriage rate of N-Nitro-L-arginine methyl ester-induced IUGR pregnant mice without detectable toxicity. In summary, the nanotechnology-assisted therapy strategy presented here not only overcomes the limitations of tadalafil in the clinical treatment of IUGR but also offers new avenues to address the treatment of other placenta-originated diseases.
Effect of propolis and polymer content on mechanical, bioadhesive and biological properties of nanostructured film forming platforms for topical drug delivery
2024, Journal of Molecular Liquids
Film form systems (FFS) composed of thermoresponsive and bioadhesive polymers have shown properties for the improvement of topical application. FFS are easy for administration, can increase the local residence time, control the drug delivery and improve the skin permeation. Propolis displays important biological properties like anticancer, healing, antimicrobial, antioxidant and can improve the structuring of FFS. It is a safe bioactive compound for wound healing and the treatment of skin diseases. However, propolis displays drawbacks for administration. The aim of this work was to evaluate the effect of polymeric and propolis composition on morphological, rheological, bioadhesive, drug release and skin permeation properties of designed FFS. In-vitro cytotoxicity, antitumoral and wound healing activity were also evaluated. Formulations composed of different amounts of polymers and propolis were proposed. The presence of propolis enhanced the bioadhesiveness and structuring of FFS. They displayed excellent capacity to form nanostructured film, displaying controlled propolis delivery and improved skin permeation. FFS were not cytotoxic and displayed in-vitro antitumoral activity and stimulated the cell migration. The selected preparations containing propolis extract (12%, w/w) and carbomer 974P or polycarbophil (0.25%, w/w) indicate a potentially advantageous role to be topically administered and suggest they are promissory formulations for clinical evaluation.
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective
2024, Advanced Drug Delivery Reviews
In recent decades, a sweeping technological wave has reshaped the global economic landscape. Fueled by the unceasing forces of digital innovation and venture capital investment, this transformative machine has left a significant mark across numerous economic sectors. More recently, the emergence of 'deep tech' start-ups, focusing on areas such as artificial intelligence, nanotechnology, and biotechnology, has infused a fresh wave of innovation into various sectors, including the pharmaceutical and cosmetic industry. This review explores the significance of innovation within the cosmetics sector, with a particular emphasis on delivery systems. It assesses the crucial process of bridging the gap between research and the market, particularly in the translation of nanotechnology into tangible real-world applications. With the rise of nanotechnology-based beauty ingredients, we can anticipate groundbreaking advancements that promise to surpass consumer expectations, ushering in a new era of unparalleled innovation in beauty products.
Biomacromolecule-based nanocarrier strategies to deliver plant-derived bioactive components for cancer treatment: A recent review
2023, International Journal of Biological Macromolecules
The quest for safe chemotherapy has attracted researchers to explore anticancer potential of herbal medicines. Owing to upsurging evidence of herbal drug's beneficial effects, hopes are restored for augmenting survival rates in cancer patients. However, phytoconstituents confronted severe limitations in terms of poor absorption, low-stability, and low bioavailability. Along with toxicity issues associated with phytoconstituents, quality control and limited regulatory guidance also hinder the prevalence of herbal medicines for cancer therapy. Attempts are underway to exploit nanocarriers to circumvent the limitations of existing and new herbal drugs, where biological macromolecules (e.g., chitosan, hyaluronic acid, etc.) are established highly effective in fabricating nanocarriers and cancer targeting. Among the discussed nanocarriers, liposomes and micelles possess properties to cargo hydro- and lipophilic herbal constituents with surface modification for targeted delivery. Majorly, PEG, transferrin and folate are utilized for surface modification to improve bioavailability, circulation time and targetability. The dendrimer and carbon nanotubes responded in high-loading efficiency of phytoconstituent; whereas, SLN and nanoemulsions are suited carriers for lipophilic extracts. This review emphasized unveiling the latent potential of herbal drugs along with discussing on extended benefits of nanocarriers-based delivery of phytoconstituents for safe cancer therapy owing to enhanced clinical and preclinical outcomes without compromising safety.
Neural cell membrane-coated DNA nanogels as a potential target-specific drug delivery tool for the central nervous system
2023, Biomaterials
A major bottleneck in drug/gene delivery to enhance tissue regeneration after injuries is to achieve targeted delivery to the cells of interest. Unfortunately, we have not been able to attain effective targeted drug delivery in tissues due to the lack of efficient delivery platforms. Since specific cell-cell interactions exist to impart the unique structure and functionality of tissues and organs, we hypothesize that such specific cellular interactions may also be harnessed for drug delivery applications in the form of cell membrane coatings. Here, we employed neural cell-derived membrane coating technique on DNA nanogels to improve target specificity. The efficacy of neural cell membrane-coated DNA nanogels (NCM-nanogels) was demonstrated by using four types of cell membranes derived from the central nervous system (CNS), namely, astrocytes, microglia, cortical neurons, and oligodendrocyte progenitor cells (OPCs). A successful coating of NCMs over DNA nanogels was confirmed by dynamic light scattering, zeta potential measurements and transmission electron microscopy. Subsequently, an overall improvement in cellular uptake of NCM-nanogels over uncoated DNA nanogels (p < 0.005) was seen. Additionally, we observed a selective uptake of OPC membrane-coated DNA nanogels (NCM-O mem) by oligodendrocytes over other cell types both in vitro and in vivo. Our quantitative polymerase chain reaction (qPCR) results also showed selective and effective gene knockdown capacity of NCM-O mem for OPC transfection. The findings in this work may be beneficial for future drug delivery applications targeted at the CNS.
Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease
2023, Ageing Research Reviews
Parkinson's disease (PD) is the second most common neurodegenerative disorder. The degeneration of dopaminergic neurons in the midbrain is primarily responsible for the onset of the disease. The major challenge faced in the treatment of PD is the blood-brain barrier (BBB), which impedes the delivery of therapeutics to targeted locations. To address this issue, lipid nanosystems have been used for the precise delivery of therapeutic compounds in anti-PD therapy. In this review, we will discuss the application and clinical significance of lipid nanosystem in delivering therapeutic compounds for anti-PD treatment. These medicinal compounds include ropinirole, apomorphine, bromocriptine, astaxanthin, resveratrol, dopamine, glyceryl monooleate, levodopa, N-3,4-bis(pivaloyloxy)- dopamine and fibroblast growth factor, which have significant potential to treat PD in the early stage. This review, in a nutshell, will pave the way for researchers to develop diagnostic and potential therapeutic approaches using nanomedicine to overcome the challenges posed by the BBB in delivering therapeutic compounds for PD.

View all citing articles on Scopus

: No conflict of interest was reported by the authors of this article.

: This work was supported by National Institutes of Health (NIH) / National Human Genome Research Institute (NHGRI) grant #1-RC1-HG005338-01 (S. M. Wolf, PI; J. McCullough, R. Hall, and J. Kahn, Co-Is), through the University of Minnesota's Consortium on Law and Values in Health, Environment & the Life Sciences.

View full text

Feature ArticleThe big picture on nanomedicine: the state of investigational and approved nanomedicine products

Abstract

From the Clinical Editor

Graphical Abstract

Section snippets

Scope of analysis

Methods

Results

Discussion

Acknowledgments

Trends Biotechnol

Drug Disc Today

Clin Chim Acta

Biomaterials

Trends Biotechnol

Int J Pharma

Biomembranes

Cancer Lett

Toxicol Appl Pharmacol

J Control Release

Bioorg Med Chem

Proc Intl Soc Mag Reson Med

Dent Mater

Biomaterials

Biomaterials

Nanowire dye-sensitized solar cells

Nat Mater

High-performance lithium battery anodes using silicon nanowires

Nat Nano

The ‘millipede’ - nanotechnology entering data storage

IEEE Trans Nanotechnol

Electronics and the single atom

Nature

Nanotechnology for molecular imaging and targeted therapy

Circulation

Nanotechnology applications in cancer

Biomed Engin

Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems

Nano Lett

Theranostic nanomedicine for cancer

Nanomedicine

The emerging nanomedicine landscape

Nature Biotechnol

Nanomedicine: drivers for development and possible impacts

JRC-IPTS, Eur

Liposomes: the next generation

Mod Drug Discov

Medical Applications of Liposomes

Concept and clinical evaluation of carrier-mediated anticancer agents

Oncologist

Nanoparticle-based therapeutics in humans: a survey

NLB

Nanoemulsion: a pharmaceutical review

Syst Rev Pharm

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

Eur Radiol

The emerging product and patent landscape for nanosilver-containing medical devices

NLB

Selected applications of nanotechnology in textiles

AUTEX Res J

Emerging technologies for point-of-care genetic testing

Expert Rev Mol Diagn

Nanomedicine - Global Strategic Business Report

Nanotechnology in Health Care to 2014 - Market Size, Market Share, Market Leaders, Demand Forecast, Sales, Company Profiles, Market Research, Industry Trends and Companies

NNI What is nanotechnology

Semiconductor nanocrystals: structure, properties, and band gap engineering

Acc Chem Res

Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology

Chem Revs

NCT00848042: Pilot study of Aurolaser™ therapy in refractory and/or recurrent tumors of the head and neck. Full text view

Strategies for the intracellular delivery of nanoparticles

Chem Soc Rev

Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells

Nano Lett

Intravascular delivery of particulate systems: does geometry really matter?

Pharm Res

Envisioned developments in nanobiotechnology—Nano2Life expert survey report

Nanotechnology and medicine / Nanotechnology medical applications. The Project on Emerging Nanotechnologies 2011

Elan Drug Technologies - NanoCrystal® Technology

FDA Basics

Feature Article
The big picture on nanomedicine: the state of investigational and approved nanomedicine products